The prevalence of major potential drug-drug interactions at a University health centre pharmacy in Jamaica

Main Article Content

Tracia-Gay Kennedy-Dixon
Maxine Gossell-Williams
Jannel Hall
Blossom Anglin-Brown


Drug Interactions, Medication Errors, Patient Safety, Pharmacists, Jamaica


Objective: To identify major potential drug-drug interactions (DDIs) on prescriptions filled at the University Health Centre Pharmacy, Mona Campus, Jamaica.

Methods: This investigation utilised a cross-sectional analysis on all prescriptions with more than one drug that were filled at the Health Centre Pharmacy              between November 2012 and February 2013. Potential DDIs were identified using the online Drug Interactions Checker database of

Results: During the period of the study, a total of 2814 prescriptions were analysed for potential DDIs. The prevalence of potential DDIs found during the study period was 49.82%. Major potential DDIs accounted for 4.7 % of the total number of interactions detected, while moderate potential DDIs and minor potential DDIs were 80.8 % and 14.5 % respectively. The three most frequently occurring major potential DDIs were amlodipine and simvastatin (n=46), amiloride and losartan (n=27) and amiloride and lisinopril (n=16).

Conclusion: This study has highlighted the need for educational initiatives to ensure that physicians and pharmacists collaborate in an effort to minimise the risks to the patients. These interactions are avoidable for the most part, as the use of online tools can facilitate the selection of therapeutic alternatives or guide decisions for closer patient monitoring and thus reduce the risks of adverse events.

Abstract 1694 | PDF Downloads 1286


1. Klepper MJ, Cobert B. Drug Safety Data: How to Analyze, Summarize and Interpret to Determine Risk. Sudbury, MA: Jones & Bartlett Learning; 2010. ISBN: 978-0763769123

2. Chatsisvili A, Sapounidis I, Pavlidou G, Zoumpouridou E, Karakousis VA, Spanakis M, Teperikidis L, Niopas I. Potential drug-drug interactions in prescriptions dispensed in community pharmacies in Greece. Pharm World Sci. 2010;32(2):187-193. doi: 10.1007/s11096-010-9365-1

3. Sepehri G, Khazaelli P, Dahooie FA, Sepehri E, Dehghani MR. Prevalence of potential drug interactions in an Iranian general hospital. Indian J Pharm Sci. 2012;74(1):75-79. doi: 10.4103/0250-474X.102548

4. Obreli Neto PR, Nobili A, Marusic S, Pilger D, Guidoni CM, Baldoni Ade O, Cruciol-Souza JM, Da Cruz AN, Gaeti WP, Cuman RK. Prevalence and predictors of potential drug-drug interactions in the elderly: a cross-sectional study in the brazilian primary public health system. J Pharm Pharm Sci. 2012;15(2):344-354.

5. Peng CC, Glassman PA, Marks IR, Fowler C, Castiglione B, Good CB. Retrospective drug utilization review: incidence of clinically relevant potential drug-drug interactions in a large ambulatory population. J Manag Care Pharm. 2003;9(6):513-522.

6. Moura CS, Prado NM, Belo NO, Acurcio FA. Evaluation of drug-drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm. 2012;34(4):547-552. doi: 10.1007/s11096-012-9642-2

7. Secoli SR, Figueras A, Lebrão ML, de Lima FD, Santos JL. Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging. 2010;27(9):759-770. doi: 10.2165/11538460-000000000-00000

8. Cruciol-Souza JM, Thomson JC.Prevalence of potential drug-drug interactions and its associated factors in a Brazilian teaching hospital. J Pharm Pharm Sci. 2006;9(3):427-433.

9. Moura C, Prado N, Acurcio F. Potential drug-drug interactions associated with prolonged stays in the intensive care unit: a retrospective cohort study. Clin Drug Investig. 2011;31(5):309-316. doi: 10.2165/11586200-000000000-00000

10. Schreiber DH, Anderson TR. Statin-induced rhabdomyolysis. J Emerg Med. 2006;31(2):177-180.

Most read articles by the same author(s)